Medical Marijuana, Inc. Subsidiary HempMeds® Co-CEO Featured in Reuters Discussing Future of Mexico’s Cannabis Industry

SAN DIEGO, Oct. 08, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that Raul Elizalde, the co-CEO of subsidiary HempMeds®, was featured in global financial news outlet Reuters discussing the future of Mexico’s legal cannabis industry.

The October 1, 2020, Reuters article entitled “Mexico, plagued by cartel wars, on cusp of legal cannabis ‘green rush’” provided coverage on pending legislation in Mexico that would make the country legal for both medicinal and recreational use. Though HempMeds® is listed in the article as a large player that is looking to get involved in these new markets, the Company has been operating and selling high-quality cannabidiol (CBD) products there for the past four years and was the first to legally import CBD to consumers in Mexico under a federal government import permit in 2016.

“We’ve made great progress in Latin America, specifically Mexico and Brazil, and are excited to see how different Mexico’s legal cannabis market looks in just a few short months,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We will continue to offer the highest-quality products and look forward to finding new ways to expand our footprint and offerings in Mexico.”

According to the article, there may soon be a huge influx of large U.S. and Canadian cannabis companies breaking into Mexico’s legal cannabis market, as well as local entrepreneurs who want to get involved. Though there is a long history of Mexico’s drug cartel influence, with these new laws the country would be able to fuel legal cannabis businesses selling in privately run sales and distribution centers.

The article was picked up by several leading global news outlets, including:

– US News & World Report

– Daily Mail

– Forbes Mexico

– Yahoo, and

– MSN.

About HempMeds®

Founded in 2012, HempMeds® was the first company to bring hemp-based cannabidiol (CBD) oil products to market in the U.S. As a subsidiary of Medical Marijuana, Inc., HempMeds is the exclusive distributor for premium brands including Real Scientific Hemp Oil™ and Dixie Botanicals®, and operates in all 50 states and 40 countries. HempMeds® is the only company to have its CBD products listed in the Prescribers’ Digital Reference (PDR), the only company invited to speak to the World Health Organization and FDA on the benefits of CBD, and one of the first to be certified by the U.S. Hemp Authority. To learn more, please visit

About Medical Marijuana, Inc.

We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company’s flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.

Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at or by visiting To see Medical Marijuana, Inc.’s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.


These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.


Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.


Public Relations Contact:
Kathryn Reinhardt
Account Supervisor
CMW Media
P. 858-264-6600
[email protected]

Investor Relations Contact:
P. (858) 283-4016
[email protected]